Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Msphere|September 24, 2020
Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53GKristen A Clarkson, Robert W Frenck, Michelle Dickey, et al.
Human Vaccines & Immunotherapeutics|August 5, 2020
Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adultsFelicia Scaggs Huang, David I Bernstein, Karen S Slobod, et al.
Vaccine|December 3, 2014
Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinationsSharon E Frey, David I Bernstein, Rebecca C Brady, et al.
The Lancet. Infectious Diseases|June 30, 2026
Efficacy of WRSs2, a live-attenuated Shigella sonnei vaccine, against shigellosis in a controlled human infection model in the USA: a phase 2, double-blind, randomised, placebo-controlled trialNadine Rouphael, Shahida Baqar, Michelle Dickey, et al.
Eclinicalmedicine|August 25, 2021
Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adultsRobert W Frenck, Valentino Conti, Pietro Ferruzzi, et al.
The Lancet. Infectious Diseases|October 22, 2019
Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trialDavid I Bernstein, Jeffrey Guptill, Abdollah Naficy, et al.
Open Forum Infectious Diseases|March 4, 2015
Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical TrialMark J Mulligan, David I Bernstein, Sharon Frey, et al.
Pageof 2